Introduction {#Sec1}
============

Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy^[@CR1]^. In recent years, an increasing number of new PTC cases have been reported each year and patients are being diagnosed with PTC at a younger age. Although it is usually accompanied by long-term and disease-specific survival, recurrence, metastases, and cancer-related deaths may occur in 10--15% of PTC patients. Thus, understanding the pathological metastasis or progression of PTC is required.

Long noncoding RNAs (lncRNAs), which are more than 200 nucleotides in length, used to be very poorly understood. However, in recent years, various functions of lncRNAs have been identified, including participating in the autophagy pathway^[@CR2],[@CR3]^, controlling cell differentiation^[@CR4]^, and acting as competing endogenous RNAs (ceRNAs) for microRNAs^[@CR2],[@CR5]^. The role of some lncRNAs as ceRNAs of miRNAs has been demonstrated in cancer metastasis and invasion^[@CR6]--[@CR9]^. For example, Lian et al. reported that lncRNA *AFAP1-AS1* acted as a ceRNA of *miR-432-5p*, to promote metastasis in nasopharyngeal carcinoma. In PTC, an increasing number of lncRNAs are being identified, including the isoform 2 of NEAT1 (*NEAT1_2*)^[@CR10]^, *SNHG15*^[@CR11]^, and *n384546*^[@CR12]^.

HOX antisense intergenic RNA myeloid 1 (*HOTAIRM1*) is a lncRNA with a length of 1052 bp. It was recently found to participate in various cancers, such as gastrointestinal malignancies^[@CR13]--[@CR16]^, breast cancer^[@CR17]^, lung cancer^[@CR18]^, glioblastoma multiforme^[@CR19]^, and acute myeloid leukemia^[@CR20],[@CR21]^. Of note, *HOTAIRM1* is under-expressed in colorectal cancer^[@CR13]^ and gastric cancer^[@CR14]^. A previous study has also shown that *HOTAIRM1* may impair the development of head and neck tumors by acting as a ceRNA and sponging *miRNA-148a*^[@CR9]^. These previous findings suggest that *HOTAIRM1* may play a crucial role as a tumor suppressor. However, to date, the role of *HOTAIRM1* in thyroid cancer has not been investigated.

On the basis of target prediction using bioinformatics analyses, *HOTAIRM1* may serve as a ceRNA for *miR-107*. Previous studies have demonstrated that *miR-107* is engaged in numerous biological processes, including cell differentiation^[@CR22]^, response to chemotherapy^[@CR23]^, insulin resistance^[@CR24]^, and metastasis^[@CR25],[@CR26]^. Accumulating evidence has shown that high levels of *miR-107* may be a risk factor in the prognostic monitoring of malignant diseases, such as gastric cancer^[@CR27]^, oropharyngeal cancer^[@CR28]^, colorectal cancer^[@CR29]^, and breast cancer^[@CR30]^. However, the association between *miR-107* and *HOTAIRM1* in the mechanism of PTC metastasis remains unknown.

In the present study, we performed quantitative reverse transcription PCR (qRT-PCR) to measure the expression of *HOTAIRM1* in PTC tissues and adjacent normal tissues and we found that *HOTAIRM1* was significantly downregulated in tumor tissues. Under-expression of *HOTAIRM1* was significantly correlated with the clinicopathological features of PTC patients, including TNM staging and lymph node metastasis. In vitro experiments showed that the overexpression of *HOTAIRM1* inhibited PTC cell proliferation, migration, and invasion and promoted apoptosis. In vivo experiments confirmed that tumor growth was suppressed after *HOTAIRM1* overexpression. In addition, high levels of *HOTAIRM1* were found to have a tumor-suppressor effect by sponging *miR-107* and regulating the expression of TDG. Taken together, the results of the current study indicated that the lncRNA, *HOTAIRM1*, might be a therapeutic target for PTC.

Results {#Sec2}
=======

*HOTAIRM1* levels were decreased in papillary thyroid cancer {#Sec3}
------------------------------------------------------------

The expression levels of *HOTAIRM1* in PTC samples were downregulated compared to the matched adjacent normal thyroid tissues (*p* \< 0.001; Fig. [1a, b](#Fig1){ref-type="fig"}). Subgroup analyses on clinical features revealed that low *HOTAIRM1* expression levels were significantly correlated with advanced stage (TIII and TIV; *p* = 0.0497; Fig. [1c](#Fig1){ref-type="fig"}, Supplementary Table [1](#MOESM1){ref-type="media"}) and lymph node metastasis (*p* \< 0.01, Supplementary Table [1](#MOESM1){ref-type="media"}). Thus, Kaplan-Meier survival analysis was performed, which confirmed that PTC patients with low *HOTAIRM1* levels (*n* = 40) had poorer overall survival than patients with high *HOTAIRM1* levels (*n* = 56; *p* = 0.028; Fig. [1d](#Fig1){ref-type="fig"}). Therefore, we performed an in vitro study to determine the function of *HOTAIRM1* in PTC. We investigated the expression of *HOTAIRM1* in Nthy-ori 3-1, NPA87, CGTHW-1, K1, B-CPAP, and TPC-1 cells and confirmed the low *HOTAIRM1* expression levels in the latter four PTC cell lines compared to the normal thyroid cell line, Nthy-ori 3-1 (Fig. [1e](#Fig1){ref-type="fig"}).Fig. 1Decreased expression of lncRNA *HOTAIRM1* in human PTC tissues and cells.**a**, **b** Relative expression levels of lncRNA *HOTAIRM1* in human PTC tissues (*n* = 96) and corresponding adjacent non-tumor tissues (*n* = 96) by qRT-PCR (\*\**p* \< 0.001). **c** *HOTAIRM1* expression levels were lower in patients with an advanced tumor stage (TIII--TIV, *n* = 32) than that in those with an early stage (TI--TII, *n* = 64, \*\**p* \< 0.001). **d** Kaplan-Meier survival analysis showed that patients with low *HOTAIRM1* expression levels (*n* = 40) had poorer overall survival than patients with high *HOTAIRM1* levels (*n* = 56, *p* = 0.028). **e** Relative expression levels in PTC cell lines (K1, B-CPAP, CGTHW-1, NPA87, and TPC-1) compared in a pairwise manner with expression levels in a normal human thyroid follicular epithelial cell line (Nthy-ori 3-1, *n* = 3, \*\**p* \< 0.001).

*HOTAIRM1* inhibited the proliferation of PTC cells in vitro and in vivo {#Sec4}
------------------------------------------------------------------------

Since *HOTAIRM1* expression levels were relatively low in B-CPAP and TPC-1 cell lines, we studied the effect of *HOTAIRM1* overexpression on the proliferation and invasion of these two PTC cell lines. B-CPAP and TPC-1 cells were divided into negative control vector (cells transfected with pcDNA3.1 plasmid vectors) and *HOTAIRM1* (cells transfected with pcDNA3.1-*HOTAIRM1*) groups. A high efficiency of *HOTAIRM1* overexpression was achieved in B-CPAP and TPC-1 cell lines using pcDNA3.1-*HOTAIRM1*, as illustrated in Fig. [2a](#Fig2){ref-type="fig"}.Fig. 2Overexpression of *HOTAIRM1* inhibited tumor growth in vitro and in vivo.**a** High levels of *HOTAIRM1* expression in B-CPAP and TPC-1 cells, achieved by transfection with pcDNA3.1-*HOTAIRM1*, were measured by qRT-PCR (*n* = 3, \*\**p* \< 0.001). **b**, **c** The effect of *HOTAIRM1* on PTC cell proliferation determined by CCK-8 and colony-formation assay (*n* = 3, \*\**p* \< 0.001); **d** Apoptosis was evaluated by flow cytometry (*n* = 3, \*\**p* \< 0.001). **e** The tumor growth curve of xenograft tumors formed from B-CPAP cells, with or without *HOTAIRM1* overexpression, in the indicated week (*n* = 5, \*\**p* \< 0.001). **f** Photographs of xenograft tumors after sacrifice. **g** The weight of xenograft tumors after sacrifice (*n* = 5, \*\**p* \< 0.001). **h** Expression of *HOTAIRM1* in xenograft tumors, assessed by qRT-PCR (*n* = 5, \*\**p* \< 0.001). **i** Representative photographs of immunohistochemical staining of Ki-67 in xenograft tumors. Scale bar: 50 μm.

The effects of *HOTAIRM1* on PTC cell proliferation in vitro were measured by a Cell Counting Kit-8 (CCK-8) assay, a colony-formation assay, and flow cytometry. The CCK-8 assay showed that *HOTAIRM1* overexpression caused a decrease in the proliferation of B-CPAP and TPC-1 cells compared with the vector group (*p* \< 0.001, Fig. [2b](#Fig2){ref-type="fig"}). The colony-formation assay demonstrated that *HOTAIRM1* overexpression attenuated the proliferation of these cells (*p* \< 0.001, Fig. [2c](#Fig2){ref-type="fig"}). The results of flow cytometry indicated that *HOTAIRM1* increased apoptosis (*p* \< 0.001, Fig. [2d](#Fig2){ref-type="fig"}).

A mouse tumor xenograft model was established to examine the effects of *HOTAIRM1* on PTC cell proliferation in vivo. B-CPAP cells from the vector or HOTAIRM1 group were injected subcutaneously on the back of each nude mouse (*n* = 5 per group). Tumor volume was measured every 7 days after the injection. B-CPAP cells with high levels of *HOTAIRM1* expression formed smaller tumors at each indicated time point, compared to vector-transfected cells (*p* \< 0.001, Fig. [2e](#Fig2){ref-type="fig"}). At the termination of the experiment (the 35th day), mice were sacrificed and the entire tumors were excised. The resected tumors in the *HOTAIRM1* group were significantly smaller and weighed less than the resected tumors in the vector group (*p* \< 0.001, Fig. [2e--g](#Fig2){ref-type="fig"}). Further, qRT-PCR results confirmed the upregulation of *HOTAIRM1* in xenograft tumors in the *HOTAIRM1* group compared with the vector group (*p* \< 0.001, Fig. [2h](#Fig2){ref-type="fig"}). In addition, immunohistochemistry (IHC) assays of the proliferation indicator, Ki-67, were performed. The percentage of Ki-67-positive cells in xenograft tumors was lower in the *HOTAIRM1* group than the vector group (Fig. [2i](#Fig2){ref-type="fig"}). Taken together, these results showed that *HOTAIRM1* overexpression efficiently impaired the proliferation of PTC cells in vitro and in vivo.

*HOTAIRM1* suppressed cell migration and invasion in vitro {#Sec5}
----------------------------------------------------------

Transwell and scratch wound healing assays were performed to evaluate the involvement of *HOTAIRM1* in the migration and invasion of B-CPAP and TPC-1 cells. The results of the transwell assay showed that *HOTAIRM1* overexpression significantly suppressed the migration and invasion of PTC cells (*p* \< 0.001, Fig. [3a, b](#Fig3){ref-type="fig"}). The results of the scratch wound healing assay confirmed that *HOTAIRM1* overexpression inhibited the migration of these cells (*p* \< 0.001, Fig. [3c](#Fig3){ref-type="fig"}). The above results demonstrated the function of *HOTAIRM1* in PTC cells and that overexpression of *HOTAIRM1* could significantly inhibit PTC cell migration and invasion in vitro.Fig. 3Overexpression of *HOTAIRM1* suppressed PTC cell migration and invasion in vitro.**a**, **b** Transwell assays were performed to evaluate the involvement of *HOTAIRM1* in the invasion of B-CPAP (**a**) and TPC-1 cells (**b**) (*n* = 3, \*\**p* \< 0.001). Scale bar: 100 μm. **c** Scratch wound healing assays were performed to assess the migration ability of B-CPAP and TPC-1 cells (*n* = 3, \*\**p* \< 0.001). Scale bar: 100 μm.

*HOTAIRM1* acted as a sponge for *miR-107* in PTC cells {#Sec6}
-------------------------------------------------------

We further investigated the underlying molecular mechanism by which *HOTAIRM1* affected PTC cell proliferation and invasion. Since there is increasing evidence showing that lncRNAs serve as ceRNAs to modulate the function of miRNAs^[@CR5]^, we utilized an online bioinformatics database (miRcode^[@CR31]^) and identified 13 microRNAs as potential competing targets of *HOTAIRM1*. Moreover, in a previous study of prognosis-related lncRNAs in ovarian cancer tissues, *HOTAIRM1* was found to regulate hub genes through seven miRNAs, including *miR-107*, *miR-103a-3p*, *miR-129-5p*, *miR-152-3p*, *miR-148a-3p*, and *miR-148b-3p*^[@CR32]^. Thus, among the candidate targets identified, we focused on *miR-107*, since high expression levels of this miRNA are considered a prognostic risk factor in several cancers^[@CR27]--[@CR30]^.

To investigate the potential relationship between *miR-107* and *HOTAIRM1* expression in PTC, we analyzed *miR-107* expression using qRT-PCR. High expression levels of *miR-107* were found in PTC tissues compared with patient-matched non-tumor tissues (*n* = 96, *p* \< 0.001, Fig. [4a](#Fig4){ref-type="fig"}). Since we previously found decreased levels of *HOTAIRM1* in PTC by qRT-PCR, a negative correlation between *miR-107* and *HOTAIRM1* levels was observed (*r* = −0.46, *p* \< 0.001, Fig. [4b](#Fig4){ref-type="fig"}). In addition, we investigated the expression of *miR-107* in Nthy-ori 3-1, NPA87, CGTHW-1, K1, B-CPAP, and TPC-1 cells and confirmed the high *miR-107* expression levels in the latter four PTC cell lines compared to the normal thyroid cell line, Nthy-ori 3-1 (Fig. [4c](#Fig4){ref-type="fig"}). There were negative correlations between HOTAIRM1 and miR-107 were found in the same panel of cell lines (Fig. [4d](#Fig4){ref-type="fig"}). Meanwhile, we verified that *miR-107* levels were reduced in *HOTAIRM1*-overexpressing PTC cells (*p* \< 0.001; Fig. [4e, f](#Fig4){ref-type="fig"}).Fig. 4*HOTAIRM1* regulated the expression of *miR-107*.**a** Relative *miR-107* expression levels determined by qRT-PCR in PTC samples (*n* = 96, \*\**p* \< 0.001). **b** Negative correlation between *HOTAIRM1* and *miR-107* levels in 96 paired PTC tissues. **c**, **d** Relative expression levels of *miR-107* in PTC cell lines (NPA87, CGTHW-1, K1, B-CPAP, and TPC-1) compared in a pairwise manner with expression levels in a normal human thyroid follicular epithelial cell line (Nthy-ori 3-1, *n* = 3, \*\**p* \< 0.001). Negative correlations between *HOTAIRM1* and *miR-107* in the same panel of cell lines. **e**, **f** Relatively low *miR-107* expression levels detected by qRT-PCR in *HOTAIRM1*-overexpressing PTC cells (*n* = 3, \*\**p* \< 0.001) and in *HOTAIRM1*-overexpressing xenograft tumor tissues (*n* = 5, \*\**p* \< 0.001). **g** Online bioinformatics software tools predicted a putative binding site between *HOTAIRM1* and *miR-107* and the binding site was mutated for dual-luciferase reporter assays. **h** A dual-luciferase reporter gene assay showed that *miR-107* decreased the luciferase activity in the *HOTAIRM1*-WT group (*n* = 3, \*\**p* \< 0.001). **i** RNA immunoprecipitation assay using an anti-Ago2 antibody and an IgG control showed a high degree of *HOTAIRM1* enrichment (*n* = 3, \*\**p* \< 0.001).

To determine whether *HOTAIRM1* binds to *miR-107*, we performed dual-luciferase reporter and RNA immunoprecipitation (RIP) assays. The predicted *miR-107*-binding site of *HOTAIRM1* was mutated, as illustrated in Fig. [4g](#Fig4){ref-type="fig"}. The results of the dual-luciferase reporter assay demonstrated that *miR-107* mimics significantly suppressed luciferase activity in the *HOTAIRM1*-WT group; however, the *miR-107* mimics were not able to bind to the mutant construct, *HOTAIRM1*-MUT and *HOTAIRM1*-WT was not able to bind to miR-NC without the seed region (*p* \< 0.001, Fig. [4h](#Fig4){ref-type="fig"}). An anti-argonaute2 (Ago2) antibody was then used to capture mature miRNAs^[@CR33]^. Data from the Ago2-RIP assay revealed that *HOTAIRM1* was enriched by the anti-Ago2 antibody, compared with the negative control (*p* \< 0.001, Fig. [4i](#Fig4){ref-type="fig"}). Taken together, these results indicated that *HOTAIRM1* may act as a ceRNA and sponge *miR-107* in PTC cells.

Inhibition of *miR-107* induced the suppression of PTC cell proliferation, migration, and invasion {#Sec7}
--------------------------------------------------------------------------------------------------

To investigate the role of *miR-107* in *HOTAIRM1*-mediated regulation, we further investigated whether *miR-107* could affect biologic activity in *HOTAIRM1*-overexpressing PTC cells. A stable increase in *miR-107* expression, compared to cells transfected with the negative control, miR-NC, was achieved in *HOTAIRM1*-overexpressing PTC cell lines using *miR-107* mimics (*p* \< 0.001, Fig. [5a](#Fig5){ref-type="fig"}).Fig. 5*miRNA-107* reversed the effects of *HOTAIRM1* overexpression.**a** Expression levels of *miR-107* in *HOTAIRM1*-overexpressing B-CPAP and TPC-1 cells transfected with miR-NC or *miR-107* mimics, assessed by qRT-PCR (*n* = 3, \*\**p* \< 0.001). **b** Micro-RNA-107 mimics reversed the *HOTAIRM1*-induced inhibition of cell proliferation (*n* = 3, \*\**p* \< 0.001). **c** *miRNA-107* mimics reversed the HOTAIRM1-induced cell apoptosis (*N* = 3, \*\**p* \< 0.001). **d**, **e** *miRNA-107* mimics restored the migration and invasion ability impaired by *HOTAIRM1* in B-CPAP (D) and TPC-1 (E) cells (*n* = 3, \*\**p* \< 0.001). Scale bar: 100 μm. **f** Migration was evaluated by wound healing assays in B-CPAP and TPC-1 cells stably overexpressing *HOTAIRM1* and transfected with miR-NC or *miR-107* mimics (*n* = 3, \*\**p* \< 0.001).

CCK-8 and flow cytometry assays demonstrated that *miR-107* promoted cell proliferation and increased apoptosis (*p* \< 0.001, Fig. [5b, c](#Fig5){ref-type="fig"}). The results of transwell and scratch wound healing assays showed that *miR-107* significantly increased cell migration and invasion in *HOTAIRM1*-overexpressing PTC cell lines (*p* \< 0.001, Fig. [5d--f](#Fig5){ref-type="fig"}). These results indicated that increased levels of *miR-107* could potentially reverse the effects of *HOTAIRM1* overexpression in vitro.

Based on the qRT-PCR results, PTC cells have high levels of *miR-107* expression (*p* \< 0.001, Fig. [6a](#Fig6){ref-type="fig"}), which was consistent with the negative correlation found between *HOTAIRM1* and *miR-107* in PTC tissues (Fig. [4b](#Fig4){ref-type="fig"}). To further verify the function of *miR-107* in PTC, we inhibited *miR-107* in B-CPAP and TPC-1 cell lines using anti-*miR-107* (*p* \< 0.001 versus the negative control, anti-NC; Fig. [6b](#Fig6){ref-type="fig"}). The results of the CCK-8, colony formation, and flow cytometry assays indicated that the inhibition of *miR-107* significantly suppressed the proliferation, migration, and invasion of B-CPAP and TPC-1 cells in vitro, compared with the negative control group (*p* \< 0.001, Fig. [6c--g](#Fig6){ref-type="fig"}). The tumorigenesis of *miR-107*-inhibited B-CPAP cells was also evaluated in a xenograft model. The inhibition of *miR-107* significantly attenuated B-CPAP cell proliferation in vivo, based on the observed decrease in tumor size and weight (*p* \< 0.001, Fig. [6h--j](#Fig6){ref-type="fig"}). Further, qRT-PCR and Ki-67 IHC results confirmed that *miR-107* expression was downregulated and cell proliferation was inhibited in xenograft tumor tissues of the anti-*miR-107* group (*p* \< 0.001, Fig. [6k--l](#Fig6){ref-type="fig"}). These results demonstrated that tumorigenesis was inhibited once the function of *miR-107* was impaired.Fig. 6The effects of *miR-107* on PTC cell proliferation and invasion.**a** The expression levels of *miR-107* in PTC cell lines and normal thyroid follicular epithelial cells (*n* = 3, \*\**p* \< 0.001). **b** The expression levels of *miR-107* were determined in *miR-107*-knockdown B-CPAP and TPC-1 cells by qRT-PCR (*n* = 3, \*\**p* \< 0.001). **c**, **d** Cell proliferation was evaluated by CCK-8 (*n* = 3, \*\**p* \< 0.001) (**c**) and colony-formation assays (*n* = 3, \*\**p* \< 0.001) (**d**) in B-CPAP and TPC-1 cells transfected with anti-*miR-107*. **e** Apoptosis was analyzed by flow cytometry (*n* = 3, \*\**p* \< 0.001). **f**, **g** Knockdown of *miR-107* inhibited the invasion of B-CPAP (**f**) and TPC-1 (**g**) cells, as determined by transwell assays (*n* = 3, \*\**p* \< 0.001). Scale bar: 100 μm. **h** Tumor growth curve of xenograft tumors formed from B-CPAP cells transfected with anti-NC or anti-*miR-107* (*n* = 5, \*\**p* \< 0.001). **i** Photographs of xenograft tumors. **j** Weight of xenograft tumors (*n* = 5, \*\**p* \< 0.001). **k** The expression levels of *miR-107* in xenograft tumor tissues assessed by qRT-PCR (*n* = 5, \*\**p* \< 0.001). **l** Representative photographs of immunohistochemical staining of Ki-67 in xenograft tumors. Scale bar: 50 μm.

TDG was an *miR-107* target gene and was indirectly regulated by *HOTAIRM1* {#Sec8}
---------------------------------------------------------------------------

In view of these results, we assumed that the target genes of *miR-107* might function directly in the pathogenesis of PTC. Therefore, we performed bioinformatics analysis (TargetScanHuman^[@CR34]^) and found that the 3′-untranslated region (UTR) of *TDG* was one of the potential binding sites of *miR-107* (Fig. [7a](#Fig7){ref-type="fig"}). Since TDG has been shown to be involved in active DNA demethylation^[@CR35],[@CR36]^, we investigated it further. We found that the expression level of TDG was lower in tumor tissues compared with non-tumor tissues (*n* = 96, Fig. [7b](#Fig7){ref-type="fig"}, *p* \< 0.001). Moreover, there was a negative correlation between *miR-107* and *TDG* levels in PTC tissues (*r* = −0.49, *p* \< 0.001, Fig. [7c](#Fig7){ref-type="fig"}). A dual-luciferase activity assay was performed to confirm that *TDG* was an *miR-107* target. The results indicated that *miR-107* mimics reduced luciferase activity in the *TDG*-WT group but not in *TDG*-MUT group (Fig. [7d](#Fig7){ref-type="fig"}, *p* \< 0.001). In both B-CPAP and TPC-1 cell lines, decreased TDG mRNA and protein expression levels were detected after increasing the expression level of *miR-107* (*p* \< 0.001, Fig. [7e, f](#Fig7){ref-type="fig"}) and western blotting results indicated that TDG protein levels increased after the inhibition of *miR-107* (Fig. [7f](#Fig7){ref-type="fig"}). These results suggested that the 3′-UTR of *TDG* was a target of *miR-107*. The functions of TDG were then investigated in PTC cells. Endogenous TDG was significantly transiently overexpressed in B-CPAP and TPC-1 cells and the efficiencies of interference were confirmed by western blotting (Supplementary Fig. [1a](#MOESM3){ref-type="media"}). A CCK-8 assay showed that TDG overexpression significantly inhibited cell proliferation (Supplementary Fig. [1b](#MOESM3){ref-type="media"}). Simultaneously, flow cytometric analysis indicated that the overexpression of TDG markedly increased the apoptosis of PTC cells (Supplementary Fig. [1c](#MOESM3){ref-type="media"}). Transwell assays demonstrated that TDG overexpression significantly decreased PTC cell migration and invasion (Supplementary Fig. [1d](#MOESM3){ref-type="media"}). To further assess the metastatic effect of TDG in vivo, TPC-1 cells with transient overexpression of TDG were injected into the tail vein of nude mice. Thus, overexpressed TDG significantly inhibited lung metastasis in vivo (Supplementary Fig. [1e](#MOESM3){ref-type="media"}). These findings strongly suggested that TDG suppressed PTC progression in vitro and in vivo.Fig. 7*TDG* was a target of *miR-107* and was increased by *HOTAIRM1* overexpression.**a** Online bioinformatics software tools predicted a putative binding site between *miR-107* and the 3′-UTR of *TDG*. This binding site was mutated for dual-luciferase reporter assays. **b** The mRNA levels of *TDG* in tissues from PTC patients (*n* = 96, \*\**p* \< 0.001). **c** Association analysis of *miR-107* and *TDG* mRNA levels in PTC tissues. **d** The dual-luciferase reporter gene assay showed that *miR-107* decreased luciferase activity in the 3′-UTR-*TDG*-WT group (*n* = 3, \*\**p* \< 0.001). **e**, **f** Relative mRNA and protein levels of TDG in B-CPAP and TPC-1 cells transfected as indicated (*n* = 3, \*\**p* \< 0.001). **g** Positive correlation between *HOTAIRM1* and TDG expression levels in 96 paired PTC tissues. **h**, **i** The mRNA and protein levels of TDG in cells with stable overexpression of *HOTAIRM1* (*n* = 3, \*\**p* \< 0.001). **j** TDG protein levels of in B-CPAP and TPC-1 cells following overexpression of *HOTAIRM1* and/or enhancement of *miR-107*.

Since a positive correlation between *HOTAIRM1* and TDG expression levels was observed in tumor tissues (*r* = 0.34, *p* = 0.0024, Fig. [7g](#Fig7){ref-type="fig"}), we sought to determine whether the regulation of TDG expression was influenced by *HOTAIRM1*. The results of qRT-PCR and western blotting indicated that the overexpression of *HOTAIRM1* increased the mRNA and protein levels of TDG (Fig. [7h--i](#Fig7){ref-type="fig"}). However, TDG protein remained under-expressed when *miR-107* expression was increased, despite the overexpression *HOTAIRM1*, in B-CPAP and TPC-1 cell lines (Fig. [7i](#Fig7){ref-type="fig"}). These results suggested that TDG expression might be enhanced by *HOTAIRM1*, in the presence of relatively low *miR-107* expression levels.

Discussion {#Sec9}
==========

Proliferation, migration, and invasion are the three main characteristics of malignant tumor cells. Our present work demonstrated that *HOTAIRM1* was significantly under-expressed in PTC tissues, while PTC patients with lymph node metastasis or higher TNM stage showed lower *HOTAIRM1* expression levels than patients with no lymph node metastases or with a lower TNM stage. This suggested that *HOTAIRM1* expression is involved in the development of PTC. Further investigation verified that overexpression of *HOTAIRM1* inhibited the proliferation, migration, and invasion of PTC cell lines in vitro, and inhibited cell proliferation in vivo, as evidenced by decreased tumor size in a mouse model of thyroid cancer. Our findings suggested the role of HOTAIRM1 as a negative regulator of PTC progression.

Recently, *HOTAIRM1* has been reported to be involved in many malignant diseases, acting as either a positive or a negative regulator in various cancers. Here, we showed that the expression levels of *HOTAIRM1* were significantly lower in PTC tissues than in adjacent normal tissues and that the expression levels of *HOTAIRM1* were lower in advanced-stage tumors than in early-stage tumors. The low levels of *HOTAIRM1* expression observed in advanced-stage PTC was consistent with the previously identified role of *HOTAIRM1* as a negative regulator of cancer progression. A study of myeloid leukemia showed that *HOTAIRM1* regulates autophagy and oncoprotein degradation during the process of myeloid cell differentiation blockade^[@CR20]^. Zheng et al. reported that the overexpression of *HOTAIRM1* suppresses the proliferation, apoptosis, migration, and invasion of prehuman hypopharyngeal tumor cells in vitro, and suppresses human hypopharyngeal tumor cell growth in vivo^[@CR9]^. The role of *HOTAIRM1* as a potential tumor suppressor has also been observed in colorectal cancer^[@CR13]^ and gastric cancer cell lines^[@CR14]^. Subsequently, our in vitro and in vivo results also supported the role of *HOTAIRM1* in inhibiting the growth, metastasis, and invasion of PTC tumors. These findings provided further evidence that *HOTAIRM1* may have a role in suppressing tumor progression.

In the past 10 years, various studies have shown that lncRNAs inhibit the expression of microRNAs through a sponge-like effect, by binding to specific sites on the microRNA and thus, interfering with the binding of the microRNA to its target gene. In the present study, the binding of *HOTAIRM1* and *miR-107* was verified by dual-luciferase reporter and RIP assays. Moreover, *HOTAIRM1* was found to negatively regulate *miR-107* in TPC-1 and B-CPAP cell lines. We also confirmed the function of *miR-107* in promoting cell growth, metastasis, and invasion in vitro and in vivo. Previous studies have shown that *miR-107* is involved in metastasis^[@CR25],[@CR26]^ and may serve as a prognostic risk factor in various cancers^[@CR27]--[@CR30]^. In view of these findings, the regulation of *miR-107* by *HOTAIRM1* may be a feasible strategy to inhibit PTC metastasis. However, the endogenous relationship between *HOTAIRM1* and *miR-107* is not exclusive, as indicated by the prediction of target microRNAs for *HOTAIRM1*. Therefore, the repression of *HOTAIRM1* may affect miRNAs other than *miR-107*. A previous study to identify prognosis-related lncRNAs in ovarian cancer tissues, showed that *HOTAIRM1* regulates hub genes through several miRNAs, including *miR-107*, *miR-103a-3p*, *miR-129-5p*, *miR-152-3p*, *miR-148a-3p*, and *miR-148b-3p*^[@CR32]^. In vitro and in vivo studies demonstrated that *HOTAIRM1* may play a negative role in the development of head and neck tumors through the *HOTAIRM1*/microRNA-148a axis^[@CR9]^. *HOTAIRM1* is also regulated by *miR-17-5p* in 5-fluorouracil-resistant colorectal cancer cells^[@CR37]^ and gastric cancer^[@CR14]^. Moreover, studies have shown that various lncRNAs, such as lncRNA nuclear paraspeckle assembly transcript 1 (*NEAT1*)^[@CR38]^, lncRNA tissue differentiation-inducing non-protein coding (*TINCR*)^[@CR39]^, and lncRNA long intervening noncoding 00467 (*LINC00467*)^[@CR40]^, modulate *miR-107* by acting as endogenous sponges. These results indicated that *HOTAIRM1* has a relatively extensive inhibitory effect on microRNAs and it may target other genes in PTC, which may have a similar impact as the interaction between *miR-107* and *HOTAIRM1*. Despite the limitations of our study, the present data may contribute to further studies of the role of *HOTAIRM1* in the progression and metastasis of PTC. The role of *miR-107* and whether it has a major or minor effect on the regulation of metastasis-related processes in PTC remains undetermined and thus, requires further investigation.

To further clarify the impact of *HOTAIRM1* and *miR-107* on PTC, the downstream regulatory mechanism of *miR-107* in PTC progression was investigated. Using bioinformatics tools, the 3′-UTR of *TDG* was predicted as one of the direct binding targets of *miR-107*. *TDG* encodes thymine DNA glycosylase, which participates in active DNA demethylation in the mammalian genome^[@CR35],[@CR36]^. Therefore, decreased TDG levels may induce the accumulation of 5-hydroxymethylcytosine, 5-carboxylcytosine, and 5-formylcytosine^[@CR35],[@CR36]^, which may lead to genomic instability and the occurrence of malignancy^[@CR41]^. For instance, previous studies have reported that low levels of TDG expression are associated with poor prognosis in breast cancer (HR = 2.178, 95% confidence interval: 1.140--4.163, *p* = 0.018)^[@CR42]^. Previously, some retrospective studies have suggested that *TDG* mutations are associated with the occurrence of tumors^[@CR43]--[@CR45]^; however, there is no direct evidence suggesting that post-transcriptional regulation by microRNAs, such as microRNA-29a^[@CR46]^, microRNA-29b^[@CR47]^, and microRNA-26a^[@CR48]^, is associated with tumors. In our study, the targeting of *TDG* by *miR-107* was verified. Moreover, we observed a negative correlation between *TDG* mRNA levels and *miR-107* in PTC tissues, but a positive correlation between *TDG* and *HOTAIRM1* levels. These data suggested a potential involvement of the *HOTAIRM1*/*miR-107*/*TDG* axis in PTC, which would be a novel pathway of the microRNA-mediated regulation of TDG in cancers. Since the present finding was only based on bioinformatics prediction and a dual-luciferase reporter assay, the evidence is not yet comprehensive and further studies are required to confirm these findings. The proposed *HOTAIRM1*/*miR-107*/*TDG* axis in PTC remains to be further explored.

In conclusion, we demonstrated that *HOTAIRM1* functioned as an oncogene in PTC. *HOTAIRM1* promotes PTC progression and acted as a ceRNA to exert malignant effects via *miR-107*/*TDG* axis. We propose a model that highlights the function of *HOTAIRM1* in regulating cell proliferation and invasion during PTC progression (Fig. [8](#Fig8){ref-type="fig"}). Collectively, our results showed that the *HOTAIRM1*/ *miR-107*/*TDG* axis has a critical role in PTC progression and is thus, a promising target for PTC therapy.Fig. 8Structure chart of the role of the *HOTAIRM1*/*miR-107/TDG* axis in PTC progression.Our combined data indicated a model whereby *HOTAIRM1* inhibited PTC cell proliferation and invasion through sponging *miR-107* to decrease the expression of *TDG*, a key DNA repair and replication proteins associated with critical aspects of cellular function.

Methods {#Sec10}
=======

Sample collection {#Sec11}
-----------------

The sampling and experimental processes were performed with the approval of the Institutional Review Board and Ethics Committee of Shanghai Tenth People's Hospital and informed written consent was obtained from 96 PTC patients who were admitted to Shanghai Tenth People's Hospital. PTC tissues and corresponding adjacent normal thyroid tissues from all patients were stored at −80 °C. Prior to thyroidectomy, none of the patients had received chemotherapy or radical treatment.

Cell culture {#Sec12}
------------

A normal human thyroid follicular epithelial cell line (Nthy-ori 3-1) and human thyroid cancer cell lines (NPA87, CGTHW-1, K1, B-CPAP, and TPC-1) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). NPA87 cells were cultivated in high-glucose DMEM supplemented with 10% fetal bovine serum (FBS), K1 cells were cultivated in DMEM supplemented with 10% FBS, and the other cell lines were cultivated in RPMI-1640 medium supplemented with 10% FBS. All cells were cultured at 37 °C under a humidified atmosphere with 5% CO~2~.

Plasmid construction and lentiviral transfection {#Sec13}
------------------------------------------------

To overexpress *HOTAIRM1*, a cDNA encoding *HOTAIRM1* was amplified by PCR and subcloned into the pCDH-CMV-MCS-EF1-Puro vector (System Biosciences, Mountain View, CA, USA). To overexpress TDG, a cDNA encoding TDG was amplified by PCR and subcloned into the pcDNA3.1(+) vector (Invitrogen Thermo Fisher, Shanghai, China). *miR-107* mimics and a negative control miRNA (miR-NC) and *miR-107* inhibitors (anti-*miR-107*) and an inhibitor control (anti-NC) were purchased from Invitrogen (Carlsbad, CA, USA). B-CPAP and TPC-1 cells were seeded in 6-well plates the day before lentivirus transduction. Lentiviruses were transduced into cells at a suitable multiplicity of infection with polybrene (8 mg/mL). After incubation for 24 h, the medium was replaced with fresh medium.

RNA extraction and qRT-PCR {#Sec14}
--------------------------

Total RNA was isolated from tissues or cells using TRIzol™ (Invitrogen) or GenElute™ Total RNA Purification Kit (Sigma-Aldrich, St. Louis, MO, USA), following the instructions of the manufacturers. Reverse transcription was performed using the PrimeScript™ RT Master Mix (Takara Biomedical Technology Co., Ltd, Beijing, China) in a S1000™ Thermal Cycler (Bio-Rad, Hercules, CA, USA). Real-time PCR was performed using the KAPA SYBR^®^ FAST qPCR Master Mix (2×) Kit (Kapa Biosystem, Wilmington, MA, USA) in a CFX96™ Real-Time System (Bio-Rad). All the primers used in these experiments are listed in Supplementary Table [2](#MOESM2){ref-type="media"}. Either *GAPDH* or *U6* was used as an endogenous reference and the 2^−ΔΔCt^ method was used to calculate expression levels.

Western blotting {#Sec15}
----------------

Protein extracts were boiled in RIPA buffer (Beyotime, Shanghai, China) and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Subsequently, the proteins were transferred to polyvinylidene fluoride membranes (0.45 μm pore diameters). Membranes were blocked in phosphate- buffered saline with 0.05% Tween-20 (PBS-T), containing 5% non-fat milk for 1 h and then incubated at 4 °C overnight with the following primary antibodies: rabbit anti-human TDG (13370-1-AP, 1:800, Proteintech, Wuhan, Hubei, China) and rabbit anti-human GAPDH (ab181602, 1:800, Abcam, Cambridge, UK). After washing with PBS-T, the membranes were hybridized with horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (ab6721, 1:2,000, Abcam, Cambridge, UK) for 1 h. Signal detection was performed using an ECL system (Amersham Pharmacia, Piscataway, NJ, USA).

Cell counting kit-8 assay {#Sec16}
-------------------------

A CCK-8 assay (Dojindo, Kumamoto, Japan) was used to determine the effect of *miR-107* and *HOTAIRM1* on cell proliferation. Briefly, cells were seeded in 96-well plates at a concentration of 2 × 10^3^ cells per well and incubated for 24, 48, 72, or 96 h. At the indicated time point, 10 μL of CCK-8 assay reagent was added and the plates were incubated for another 4 h. A SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA) was used to measure the absorbance at 450 nm.

Plate colony-formation assay {#Sec17}
----------------------------

Briefly, after 24 h of transfection, B-CPAP and TPC-1 cells were initially seeded into 3.5 cm culture dishes at a density of 800 cells per dish and maintained in medium containing 10% FBS, which was refreshed every 2 days. After the cells had been incubated for approximately 2 weeks at 37 °C in 5% CO~2~, the resulting colonies were visible to the naked eye. The cells were fixed with 4% paraformaldehyde for 15 min before staining with 0.1% crystal violet for 15 min and then counted. The colony numbers were counted using ImageJ software (National Institutes of Health, Bethesda, MD, USA) and manually counted from three randomly chosen fields. Experiments were tested in triplicate.

Flow cytometric analysis of cell apoptosis {#Sec18}
------------------------------------------

A fluorescein-conjugated annexin V (annexin V-FITC)/propidium iodide (PI) staining kit (BD Biosciences, San Jose, CA, USA) was used to detect apoptosis, following the manufacturer's instructions. A FACS Calibur FCM instrument (BD Biosciences) was used to observe apoptosis. In brief, 48 h after transfection, cells were suspended in 100 μL of binding buffer at a concentration of 1 × 10^5^ cells/mL, after which 5 μL of FITC-annexin V and 5 μL of PI were added to the solution. After incubating for 15 min at room temperature protected from light, 400 μL of binding buffer was added and apoptosis was assessed within 1 h. Experiments were performed in triplicate to help reduce errors. FACS Diva software (BD Biosciences) was used for data analysis.

Cell invasion and migration assays {#Sec19}
----------------------------------

For transwell migration assays, transfected B-CPAP and TPC-1 cells transfected cells (4 × 10^5^) were plated in the top chamber and a noncoated membrane (24-well insert; pore size, 8 μm; BD Biosciences) was polymerized in transwell inserts for 45 min at 37 °C. In both assays, cells were plated in the top chamber in medium without serum and the lower chamber was filled with 20% FBS (GIBCO BRL, Grand Island, NY, USA) as a chemoattractant. Cells were incubated for 24 h and those that did not migrate or invade through the pores were removed with a cotton swab. Cells that migrated to the lower surface of the membrane were fixed and stained with 0.1% crystal violet. The cells on the bottom of the membrane were counted from five different microscopic fields and the average number was calculated.

Scratches extending the length of each well were made on the cellular surface of each well of six-well plates containing B-CPAP and TPC-1 cells, using standard 200 μL pipette tips. Cells within the wound area were washed with PBS and the images were photographed under an inverted microscope (Leica Microsystems) 24 h later.

Animal experiments {#Sec20}
------------------

All animal studies were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee of Shanghai Tenth People's Hospital. Six-week-old nude mice (*n* = 20) were purchased from SLAC Laboratory Animal Co., Ltd (Shanghai, China) and were randomly divided into four groups and no blinding was done. Serum-free suspensions (1 × 10^7^/mL) of B-CPAP cells transfected with pcDNA3.1-*HOTAIRM1*, pcDNA3.1vector (as negative control), anti-NC, or anti-*miR-107* were injected subcutaneously on the back of each mouse (0.2 mL). When the tumor grew to approximately 100-200 mm^3^, the tumor volume was calculated using the following formula: 1/2 × L^2^ × W, where L is the length (mm) and W is the width (mm) of the tumor. The average volume of the tumor was measured three times every 7 days. At the termination of the experiment (the 35th day), mice were sacrificed and the tumors were excised for volume and weight measurements. Total RNA was isolated and the expression level of *HOTAIRM1* was determined by qRT-PCR.

To establish an in vivo lung metastasis model, 1 × 10^6^ cells were intravenously injected into the lateral tail vein of nude mice (*n* = 5 per group). The mice were measured using a bioluminescence system (Titertek Berthold, Pforzheim, Germany) and at week 8, the mice were sacrificed. Thereafter, to analyze the presence of metastatic nodules, the lungs were fixed, photographed, preserved, and stained with hematoxylin and eosin.

Immunohistochemistry assay {#Sec21}
--------------------------

A Ki-67 cell proliferation kit (Sangon Biotech, Shanghai, China) was used to evaluate cell proliferation in xenograft tumors, following the manufacturer's instructions.

Dual-luciferase activity assay {#Sec22}
------------------------------

Luciferase plasmids containing wild-type (pmirGLO-HOTAIRM1-WT) or mutated (pmirGLO-HOTAIRM1-MUT) putative *HOTAIRM1* binding sites used to target *miR-107* were generated. Luciferase plasmids containing wild-type (pmirGLO-TDG-WT) or mutated (pmirGLO-TDG-MUT) putative *miR-107*-binding sites from the 3′-UTR of *TDG* were also generated. All plasmids were obtained from Genepharma (Shanghai, China).

To detect binding between *HOTAIRM1* and *miR-107*, pmirGLO-HOTAIRM1-WT or pmirGLO-HOTAIRM1-MUT were co-transfected with *miR-107* mimics or miR-NC (Invitrogen) into HEK-293T cells using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA). Cells were harvested 48 h after transfection and luciferase activity was measured as chemiluminescence using a luminometer (PerkinElmer Life Sciences, Boston, MA, USA) and a dual-luciferase reporter assay system (Promega, Madison, WI, USA), according to the manufacturer's protocol. The detection of binding between the 3′-UTR of *TDG* and *miR-107* was performed in the same way.

RNA immunoprecipitation assay {#Sec23}
-----------------------------

RIP assays were performed, using B-CPAP and TPC-1 cell lines, to investigate the binding of *miR-107* to *HOTAIRM1*. An Imprint RIP kit was used according to the manufacturer's instructions (Sigma-Aldrich), with an anti-Ago2 antibody (Sigma-Aldrich). Total RNA was isolated using a GenElute™ Total RNA Purification Kit (Sigma-Aldrich) and the final analysis was performed using qRT-PCR, as described above.

Bioinformatics analyses {#Sec24}
-----------------------

The prediction of candidate target microRNAs of *HOTAIRM1* and the prediction of potential binding sites were performed using the online tool, miRcode^[@CR31]^ (<http://www.mircode.org/>). Results were retrieved using the gene symbol, "HOTAIRM1." The site conservation parameter was set as "most primates" and the other parameters were set as default.

The prediction of putative target genes for *miR-107* was performed using the online tool, TargetScanHuman^[@CR34]^ (<http://www.targetscan.org/vert_71/>). Results were retrieved using the microRNA name, 'miR-107' and the other parameters were set as default.

Statistical analysis {#Sec25}
--------------------

Statistical analyses were performed using SPSS statistics 22 software (IBM, Armonk, NY, USA) and GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA). All data are presented as the mean ± standard deviation and all in vitro experiments were performed in triplicate. The expression data for *HOTAIRM1*, *miR-107*, and *TDG* conformed to a normal distribution and the differences in expression levels between tumor and paired normal tissues were evaluated by a paired Student's *t*-test. The analysis of correlation between lncRNA *HOTAIRM1* expression and clinicopathological features of PTC patients was performed by Chi-square test. Pearson's correlation analysis was performed to assess the correlation between *HOTAIRM1*/*mir-107*, *mir-107*/*TDG*, and *HOTAIRM1*/*TDG*. *P*-values less than 0.05 were considered statistically significant.
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